NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Glomerulonephritis


Return to Library

Free Glomerulonephritis Articles


Researchers from University of London, Imperial College provide details of new studies and findings in the area of glomerulonephritis



2009 JUL 20 - (NewsRx.com) -- "The P2X(7), receptor is a ligand-gated cation channel that is normally expressed by a variety of immune cells, including macrophages and lymphocytes. Because it leads to membrane blebbing, release of IL-1 beta, and cell death by apoptosis or necrosis, it is a potential therapeutic target for a variety of inflammatory diseases," investigators in London, the United Kingdom report.

"Although the P2X(7) receptor is usually not detectable in normal renal tissue, we previously reported increased expression of both mRNA and protein in mesangial cells and macrophages infiltrating the glomeruli in animal models of anti body-mediated glomerulonephritis. In this study, we used P2X(7)-knockout mice in the same experimental model of glomerulonephritis and found that P2X(7) deficiency was significantly renoprotective compared with wild-type controls, evidenced by better renal function, a striking reduction in proteinuria, and decreased histologic glomerular injury. In addition, the selective P2X(7) antagonist A-438079 prevented the development of antibody-mediated glomerulonephritis in rats," wrote S.R.J. Taylor and colleagues, University of London, Imperial College.

The researchers concluded: "These results support a proinflammatory role for P2X(7) in immune-mediated renal injury and suggest that the P2X(7) receptor is a potential therapeutic target.."

Taylor and colleagues published their study in the Journal of the American Society of Nephrology (P2X(7) Deficiency Attenuates Renal Injury in Experimental Glomerulonephritis. Journal of the American Society of Nephrology, 2009;20(6):1275-1281).

For additional information, contact F.W.K. Tam, University of London Imperial College, Hammersmith Hospital, Division Medical, Imperial College Kidney & Transplant Institute, Cane Rd., London W12, UK.

The publisher of the Journal of the American Society of Nephrology can be contacted at: American Society Nephrology, 1725 I St., NW Ste. 510, Washington, DC 20006, USA.

Keywords: United Kingdom, London, Apoptosis, Experimental Glomerulonephritis, Glomerulonephritis, Kidney, Necrosis, Nephrology, Therapy, Treatment, University of London, Imperial College.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login